Targeted Therapy Mechanisms: A Primer for Practicing Oncologists

Recent Trends in Targeted Therapy Development

Over the past several years, the landscape of targeted therapy has expanded beyond classic tyrosine kinase inhibitors and monoclonal antibodies. Novel platforms such as antibody–drug conjugates (ADCs), bispecific T‑cell engagers (BiTEs), and chimeric antigen receptor (CAR)‑T cell therapies have entered routine practice for certain hematologic and solid tumors. Another notable trend is the rise of small‑molecule degraders, including proteolysis‑targeting chimeras (PROTACs), which exploit the ubiquitin‑proteasome system to eliminate oncogenic proteins rather than merely inhibit them. Combination regimens—pairing targeted agents with immune checkpoint inhibitors or with other molecularly directed drugs—are increasingly common, though they bring added complexity in toxicity management and sequencing.

Background: How Targeted Therapy Differs from Traditional Chemotherapy

Unlike cytotoxic chemotherapy, which primarily attacks rapidly dividing cells, targeted therapies are designed to interfere with specific molecular pathways that drive cancer growth and survival. Their effectiveness depends on the presence of a particular biomarker—such as a gene mutation, amplification, translocation, or protein overexpression—that can be identified through genomic or proteomic profiling. Early successes in chronic myeloid leukemia (BCR‑ABL inhibitors) and HER2‑positive breast cancer (trastuzumab) established the paradigm. Since then, the number of actionable targets has grown substantially, and regulatory approvals have shifted toward biomarker‑selected indications. This molecular approach has also spurred the development of “liquid biopsy” techniques for non‑invasive detection of resistance mutations and minimal residual disease.

Key Concerns for Practicing Oncologists

• Resistance mechanisms: Acquired resistance, whether through secondary mutations, pathway bypass, or phenotypic plasticity, remains a major barrier. Clinicians must be aware of common resistance patterns for each agent and how to use sequential therapy or combination strategies.
• Tumor heterogeneity: The same tumor can harbor multiple subclones with different genetic alterations, complicating biopsy interpretation and treatment selection. Dynamic changes over time further challenge decision‑making.
• Cost and access: Many targeted therapies carry high price tags, and insurance coverage may vary by biomarker test availability and regional policies. Prior authorization requirements and formulary restrictions can delay treatment.
• Adverse event profiles: Although often less broadly myelosuppressive than chemotherapy, targeted agents have unique toxicities (e.g., interstitial lung disease with some kinase inhibitors, cytokine release syndrome with BiTEs/CAR‑T, peripheral neuropathy with ADCs) that require proactive monitoring and management.
• Patient selection: Determining which biomarker tests to order, when to re‑biopsy, and how to interpret variants of unknown significance is a growing challenge. Guidelines from professional societies are helpful but may lag behind emerging data.

Likely Impact on Clinical Practice

The continued refinement of targeted therapy mechanisms is expected to improve outcomes for molecularly defined patient subsets, but it will also demand greater specialization. Multidisciplinary tumor boards that include molecular pathologists, genetic counselors, and clinical pharmacists will become more integral to routine care. As more agents receive approval for adjuvant or neoadjuvant use, the timing of targeted therapy relative to surgery and radiation will require careful coordination. Additionally, the integration of targeted agents with immunotherapy may produce durable responses in some tumors where single‑agent activity is limited, though overlapping immune‑mediated toxicities must be managed.

What to Watch Next

• Next‑generation degraders and glues: Beyond PROTACs, molecular glues that induce proximity between an E3 ligase and a target protein are in early clinical trials, potentially expanding the druggable proteome.
• Advances in liquid biopsy: Methylation‑based assays and multi‑analyte platforms may allow earlier detection of resistance and more dynamic monitoring of tumor evolution, guiding real‑time therapy switches.
• Artificial intelligence in target discovery: Machine learning models that predict drug–target interactions and polypharmacology could accelerate the identification of new indications for existing agents and reduce development timelines.
• Regulatory and reimbursement shifts: Payers are increasingly requiring evidence of biomarker‑based patient selection and comparative effectiveness. Expanded coverage for comprehensive genomic profiling may become a benchmark for access to targeted therapies.